SNX-2112, also known as PF 04928473, is an Hsp90 inhibitor which is currently undergoing multiple phase 1 clinical trials. In all cell lines, SNX-2112 led to degradation of MET, HER-2, EGFR, and AKT as well as abrogation of Ras/Raf/MEK/MAPK and PI3K/AKT signaling, followed by complete cell cycle arrest.

Product information

CAS Number: 908112-43-6

Molecular Weight: 464.48

Formula: C23H27F3N4O3

Synonym:

PF-04928473

Chemical Name: 4-(6, 6-dimethyl-4-oxo-3-(trifluoromethyl)-4, 5, 6, 7-tetrahydro-1H-indazol-1-yl)-2-(((1r, 4r)-4-hydroxycyclohexyl)amino)benzamide

Smiles: CC1(C)CC2=C(C(=O)C1)C(=NN2C1=CC(N[C@@H]2CC[C@@H](O)CC2)=C(C=C1)C(N)=O)C(F)(F)F

InChiKey: ZFVRYNYOPQZKDG-MQMHXKEQSA-N

InChi: InChI=1S/C23H27F3N4O3/c1-22(2)10-17-19(18(32)11-22)20(23(24,25)26)29-30(17)13-5-8-15(21(27)33)16(9-13)28-12-3-6-14(31)7-4-12/h5,8-9,12,14,28,31H,3-4,6-7,10-11H2,1-2H3,(H2,27,33)/t12-,14-

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: Soluble in DMSO, not in water

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

Products are for research use only. Not for human use.